ArticleACG case reports journal2026
Desquamating Esophagitis in the Era of Immune Checkpoint Inhibitors: A Rare Upper Gastrointestinal Manifestation.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multinational pharmacovigilance assessment of drug-associated esophageal ulceration and perforation: evidence from FAERS, JADER, and Canada Vigilance.BMC pharmacology & toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desquamating esophagitis is a rare sloughing disorder of the esophageal mucosa most commonly associated with medications, autoimmune disease, or mucosal injury. Immune checkpoint inhibitors rarely cause esophageal involvement. We report a case of a 65-year-old woman with metastatic cervical cancer who developed progressive dysphagia 3 months after initiation of pembrolizumab. Endoscopy revealed severe proximal stenosis associated with desquamating esophagitis. She required frequent dilations but demonstrated marked and durable resolution after systemic corticosteroid therapy. This case highlights desquamating esophagitis as an uncommon immune-related adverse event and emphasizes that timely immunosuppression can reverse refractory inflammatory stricture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.